cyproterone acetate has been researched along with Disease Exacerbation in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 6 (54.55) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Antoniou, N; Calais da Silva, F; Calais da Silva, FM; Gonçalves, F; Kliment, J; Marques Queimadelos, A; Oliver, T; Pastidis, S; Robertson, C; Santos, A; Whelan, P | 1 |
| Collette, L; de Reijke, TM; Schröder, FH | 1 |
| Collette, L; de Reijke, TM; Debois, M; Kurth, KH; Mattelaer, J; Pavone-Macaluso, M; Schröder, FH; van Velthoven, RF; Whelan, P | 1 |
| Costantini, A; Di Silverio, F; Serio, M | 1 |
| Danielsen, HE; Jørgensen, T; Kaalhus, O; Müller, C; Tveter, KJ | 1 |
| Azmatullah, S; Fellows, GJ; Gingell, JC; O'Boyle, PJ; Thorpe, SC | 1 |
| Atahan, O; Kayigil, O; Metin, A | 1 |
| de Pauw, M; de Voogt, HJ; Klijn, JG; Schröder, FH; Studer, U; Sylvester, R | 1 |
| Boccardo, F; Brune, D; Bruynseels, J; De Porre, P; Debruyne, FJ; Denis, L; Fradet, Y; Janssens, M; Johansson, JE; Marberger, JM; Murray, R; Rassweiler, J; Tyrrell, C; Vangeneugden, T | 1 |
| Barkin, J; Chetner, M; Chin, J; Fradet, Y; Goldenberg, SL; Jewett, M; Klotz, LH; Laplante, S | 1 |
| Gleave, M; Goldenberg, SL; Klotz, L | 1 |
1 review(s) available for cyproterone acetate and Disease Exacerbation
| Article | Year |
|---|---|
Neoadjuvant hormone therapy: the Canadian trials.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Canada; Cyproterone Acetate; Disease Progression; Flutamide; Humans; Leuprolide; Male; Neoadjuvant Therapy; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate | 2000 |
8 trial(s) available for cyproterone acetate and Disease Exacerbation
| Article | Year |
|---|---|
Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Uroncological Group.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyproterone Acetate; Disease Progression; Europe; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Sexuality; Survival Rate; Time Factors; Triptorelin Pamoate | 2014 |
Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Cyproterone Acetate; Disease Progression; Flutamide; Humans; Male; Middle Aged; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Sensitivity and Specificity; Soft Tissue Neoplasms; Survival Analysis | 2003 |
Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Cyproterone Acetate; Disease Progression; Flutamide; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Survival Rate | 2004 |
Extent of disease based on initial bone scan: important prognostic predictor for patients with metastatic prostatic cancer. Experience from the Scandinavian Prostatic Cancer Group Study No. 2 (SPCG-2).
Topics: Androgen Antagonists; Bone and Bones; Bone Neoplasms; Combined Modality Therapy; Cyproterone Acetate; Disease Progression; Follow-Up Studies; Humans; Male; Orchiectomy; Prognosis; Prospective Studies; Prostatic Neoplasms; Radionuclide Imaging; Severity of Illness Index | 1995 |
A prospective, randomised study to compare goserelin acetate (Zoladex) versus cyproterone acetate (Cyprostat) versus a combination of the two in the treatment of metastatic prostatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyproterone Acetate; Disease Progression; Goserelin; Humans; Male; Middle Aged; Prospective Studies; Prostatic Neoplasms; Safety | 1996 |
Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. Final analysis o
Topics: Acid Phosphatase; Administration, Intranasal; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Carcinoma; Cause of Death; Cyproterone Acetate; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Injections, Subcutaneous; Male; Middle Aged; Orchiectomy; Pain Measurement; Proportional Hazards Models; Prospective Studies; Prostatic Neoplasms; Survival Rate; Treatment Outcome | 1998 |
Liarozole--a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study Group.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Cyproterone Acetate; Disease Progression; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate | 1998 |
CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Canadian Urologic Oncology Group.
Topics: Androgen Antagonists; Chemotherapy, Adjuvant; Cyproterone Acetate; Disease Progression; Humans; Male; Preoperative Care; Prospective Studies; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Time Factors | 1999 |
2 other study(ies) available for cyproterone acetate and Disease Exacerbation
| Article | Year |
|---|---|
Use of the LHRH analogue zoladex depot alone and in combination with cyproterone acetate in the treatment of advanced prostatic cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cyproterone Acetate; Disease Progression; Goserelin; Humans; Male; Neoplasm Staging; Prostatic Neoplasms; Survival Analysis; Treatment Outcome | 1989 |
Cyproterone acetate monotherapy in advanced prostatic carcinoma.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Carcinoma; Cyproterone Acetate; Disease Progression; Follow-Up Studies; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Testosterone; Treatment Outcome | 1997 |